What was the overall market valuation for rheumatic fever in 2024?

The overall market valuation for rheumatic fever was $67.81 Million in 2024. Read More

What is the projected market valuation for rheumatic fever by 2035?

The projected market valuation for rheumatic fever is $100.5 Million by 2035. Read More

What is the expected CAGR for the UK rheumatic fever market during the forecast period 2025 - 2035?

The expected CAGR for the UK rheumatic fever market during the forecast period 2025 - 2035 is 3.64%. Read More

What are the main segments of the rheumatic fever market?

The main segments of the rheumatic fever market include Diagnosis, Treatment, Distribution Channel, and End-User. Read More

What was the valuation for the Diagnosis segment in 2024?

The Diagnosis segment had a valuation of $67.81 Million in 2024, with specific tests like Physical Exam and Echocardiogram contributing significantly. Read More

How much is the Treatment segment projected to be worth by 2035?

The Treatment segment is projected to be worth between $67.81 Million and $100.5 Million by 2035. Read More

What is the distribution channel breakdown for rheumatic fever treatments?

The distribution channel breakdown includes Retail Pharmacies, Hospital Pharmacies, and Others, with valuations ranging from $12.81 Million to $45.0 Million. Read More

What are the expected end-user segments for rheumatic fever treatments?

Expected end-user segments include Hospitals and Clinics, Diagnostic Centers, and Others, with valuations between $17.81 Million and $45.0 Million. Read More

How does the market for rheumatic fever in 2025 compare to 2024?

The market for rheumatic fever in 2025 is anticipated to grow from the 2024 valuation of $67.81 Million, reflecting the projected growth trends. Read More

UK Rheumatic Fever Market

Q: Which companies are key players in the rheumatic fever market?

Key players in the rheumatic fever market include GlaxoSmithKline, Sanofi, Pfizer, Merck & Co, AstraZeneca, Bristol-Myers Squibb, Novartis, AbbVie, and Roche. Read More

ID: MRFR/HC/55224-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

UK Rheumatic Fever Market Research Report By Diagnosis (Physical Exam, Blood Test, Electrocardiogram, Other), By Treatment (Pharmacotherapy) and By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

UK Rheumatic Fever Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)3.64%

2024 Market Size$ 67.81 Million

2025 Market Size$ 70.28 Million

2035 Market Size$ 100.5 Million

Key Players

GlaxoSmithKline

Sanofi

Pfizer

Merck & Co

AstraZeneca

Bristol-Myers Squibb

Trends

Increased Focus on Prevention
Advancements in Diagnostic Technologies
Collaboration for Comprehensive Care

Opportunities

Rising Awareness and Education
Government Initiatives and Funding
Rising Incidence of Rheumatic Fever

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Diagnosis (USD Million)
  1. 4.1.1 Physical Exam
  2. 4.1.2 Blood Test
  3. 4.1.3 Electrocardiogram
  4. 4.1.4 Echocardiogram
2. 4.2 Pharmaceutical, BY Treatment (USD Million)
  1. 4.2.1 Pharmacotherapy
  2. 4.2.2 Others
3. 4.3 Pharmaceutical, BY Distribution Channel (USD Million)
  1. 4.3.1 Retail Pharmacies
  2. 4.3.2 Hospital Pharmacies
  3. 4.3.3 Others
4. 4.4 Pharmaceutical, BY End-User (USD Million)
  1. 4.4.1 Hospitals and Clinics
  2. 4.4.2 Diagnostic Centers
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Sanofi (FR)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bristol-Myers Squibb (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 UK MARKET ANALYSIS BY TREATMENT
4. 6.4 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 UK MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY DIAGNOSIS, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY TREATMENT, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY TREATMENT, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Rheumatic Fever Market Segmentation

UK Rheumatic Fever Market By Diagnosis (USD Million, 2025-2035)

Physical Exam
Blood Test
Electrocardiogram
Echocardiogram

UK Rheumatic Fever Market By Treatment (USD Million, 2025-2035)

Pharmacotherapy
Others

UK Rheumatic Fever Market By Distribution Channel (USD Million, 2025-2035)

Retail Pharmacies
Hospital Pharmacies
Others

UK Rheumatic Fever Market By End-User (USD Million, 2025-2035)

Hospitals and Clinics
Diagnostic Centers
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”